Assays that can determine the response of tumor cells to cancer therapeutics could greatly aid the selection of drug regimens for individual patients. However, the utility of current functional assays is limited, and predictive genetic biomarkers are available for only a small fraction of cancer therapies. We found that the single-cell mass accumulation rate (MAR), profiled over many hours with a suspended microchannel resonator, accurately defined the drug sensitivity or resistance of glioblastoma and B-cell acute lymphocytic leukemia cells. MAR revealed heterogeneity in drug sensitivity not only between different tumors, but also within individual tumors and tumor-derived cell lines. MAR measurement predicted drug response using samples as small as 25 ml of peripheral blood while maintaining cell viability and compatibility with downstream characterization. MAR measurement is a promising approach for directly assaying single-cell therapeutic responses and for identifying cellular subpopulations with phenotypic resistance in heterogeneous tumors.
A r t i c l e s
The choice of drug regimens for individual cancer patients has historically been based on treatment responses observed in large studies across heterogeneous populations. The shortcomings of this approach have motivated a broad effort to personalize treatment decisions for each patient based on the presence or absence of genetic, epigenetic or other biomarkers in an individual tumor 1, 2 . Although population-based studies have been successful in some instances (e.g., in lung cancers with mutations of EGFR or rearrangements involving ALK), the vast majority of cancer therapeutics have no known markers for susceptibility or resistance 3 . Even when marker-based predictions can be made, they do not guarantee patient response, as many are the result of correlations from populationbased studies 4, 5 .
The second major shortcoming of nearly all available biomarkers is that they are derived from analyses of bulk tumor populations, and therefore do not predict the emergence of resistant subpopulations. More sensitive approaches of genetic characterization, such as singlecell sequencing, are becoming increasingly common as research platforms, but are not yet amenable to a clinical setting 6, 7 . These approaches also suffer from the same shortcoming as bulk assays, that is, the lack of predictive genetic or transcriptional markers.
In contrast with most biomarkers, functional assays can provide phenotype-driven predictors of therapeutic response that represent the integrated output of multiple parameters, including genetic, epigenetic, environmental and other variables that determine response. Detection of clinical response in a patient following treatment initiation is currently measured either by imaging to quantify bulk tumor volume or by directly measuring tumor burden within a compartment (e.g., peripheral blast counts). However, these assessments are delayed in time (ranging from days to months), and clinical indicators are only useful for making post hoc treatment decisions. In the ideal scenario, therapeutic functional assays would be used to guide selection of treatment that would induce response and thereby avoid problematic side effects from inefficacious therapies.
Although functional assays are essential clinical tools for assessing the antibiotic susceptibility of microbes, no such approaches have been widely adopted for patients with cancer 8, 9 . Existing platforms to measure cancer cell growth, such as ATP-based assays (CellTiter-Glo), require extended time in culture and a large number of tumor cells 10 . This precludes their use for the large majority of patients, who have limited amounts of cancer tissue available. Furthermore, these bulk A r t i c l e s approaches are ill-suited for characterizing therapeutic susceptibility of subpopulations that exist in heterogeneous tumors 10 .
An ideal functional assay for predicting therapeutic response in patients with cancer would accurately measure responses to both single drugs and drugs in combination; require minimal sample input; avoid artifacts that result from long-term, in vitro culture; quantify therapeutic response at the single-cell level; return results in a time frame that is conducive to therapeutic decision making; and maintain cell viability to allow for downstream functional and molecular interrogations.
We developed an approach for functionally assessing the therapeutic sensitivity of single cancer cells by weighing each cell repeatedly over a 15-min period in a suspended microchannel resonator (SMR) (Fig. 1a) [11] [12] [13] , either in the presence or absence of cancer therapeutics. Resonator-based approaches have been used to measure an array of cellular physical properties 14 and, in one preliminary study, response to therapeutics 15 . Following the incubation of tumor cells with drug, the SMR was able to detect changes in the growth of single cells to predict therapeutic response without the need for extended culture. To validate this approach, we applied the SMR to traditional cancer cell lines, patient-derived cell lines (PDCLs) and primary leukemia cells.
RESULTS

MAR measurement
The SMR is a cantilever-based microfluidic mass sensor that measures the buoyant mass (referred to hereafter simply as mass) of live single cells with a resolution near 50 fg, which is highly precise given that the average buoyant mass of a hematopoietic cell is ~75 pg 12 . Cells were measured in suspension while under culture conditions, with controlled media temperature and CO 2 concentration to maintain cell viability and growth 13 . A series of mass measurements was made on an individual cell every ~30 s for ~15 min, allowing for determination of the MAR, which was defined as the change in mass over time (Fig. 1a) 12 . In addition to the MAR, we also used the absolute single-cell mass as a biomarker, which was determined for each cell during the MAR measurement. By measuring MAR on multiple cells from the same population, the SMR revealed heterogeneity in mass and MAR across the population, rather than an average of the tumor bulk. The degree to which mass and MAR behaved as independent biomarkers varied depending on conditions and cell type. Although linear discriminate analysis (LDA) maximized the predictive capability of these two biomarkers, we used a simplified metric of MAR normalized by mass for most of our experiments. 
A r t i c l e s
Single-cell MARs reveal tumor growth heterogeneity To better characterize the platform's performance, we applied this method to two cancer cell types known to be viable and proliferate in suspended cell culture: glioblastoma (GBM) and acute leukemias. First, we analyzed a fast growing GBM-PDCL (BT145), which grows as freefloating 'stem-like' cells and tumorspheres, as well as primary leukemia cells isolated directly from mice with genetically engineered acute lymphoblastic leukemia (ALL) expressing the fusion protein BCR-ABL. Consistent with our previous findings 12 , the SMR was able to quantify MAR of single cells over ~15-min intervals with high signalto-noise ratios in both tumor types (Fig. 1b) . During this time, the cells acquired less than a few picograms of biomass. This is equivalent to an increase in cell diameter on the order of only 10 nm.
To determine whether cell proliferation potential could be maintained after passage through the SMR, we isolated single BT145 GBM cells after MAR measurement and then assayed them for their ability to form tumorspheres. Overall, 14 (36%) of 39 single cells formed tumorspheres compared with 217 (45.2%) of 480 single cells isolated directly from a bulk culture (P = 0.26; Supplementary Fig. 1 ). Thus, MAR measurement had no statistically significant effect on viability or stem-like cell phenotype.
The heterogeneity of single-cell growth across cell lines or patient models has not been well characterized. In BT145 cells, MAR measurements enabled the delineation of different growth populations, identifying cells of both large and small mass with positive, zero and negative MAR (Fig. 1b) . GBM tumors are known to harbor an exceptionally diverse admixture of growing, senescent, quiescent and dying cells 16, 17 . Examination of BT145 by immunohistochemistry also confirms the presence of these heterogeneous properties in PDCLs (Supplementary Fig. 2 ). Thus, heterogeneity of MAR and mass in this line seems to parallel the known growth heterogeneity and morphological diversity of cells seen in primary GBMs. In contrast, almost all primary BCR-ABL ALL cells had positive MARs that monotonically increased with cell mass (Fig. 1b) .
To determine the range of growth diversity that might exist across patients in a single tumor type, we measured MARs of single cells from seven different GBM-PDCLs with diverse genotypes (Supplementary Table 1 ) over three successive passages ( Supplementary Fig. 3 ) 18 . MAR measurements revealed significant inter-and intra-PDCL heterogeneity across the seven PDCLs with single-cell diversity in both MAR and mass. These findings were in stark contrast with the homogeneity of MARs across conventional hematopoietic cell lines, such as the L1210 leukemia cell line and the murine lymphoblastoid BaF3 cell line, which was engineered to express BCR-ABL (BaF3 BCR-ABL) (Fig. 1c) . Such homogeneity did not appear to be related to the advanced age and passage of these lines, as the conventional GBM cell line U87 exhibited significant MAR heterogeneity. Some lines, such as BT159 and BT145, had more homogenous patterns of cell proliferation, whereas BT320 and BT179 exhibited the most heterogeneous phenotypes, which we confirmed using immunohistochemistry analysis ( Supplementary Fig. 2 ). The extent of growth heterogeneity in individual GBM-PDCLs was maintained across consecutive passages ( Supplementary Fig. 3 ), suggesting that intra-tumoral diversity in growth is an inherent property of GBM PDCLs even during in vitro propagation.
MAR predicts cell line sensitivity to targeted therapy
To test the ability of MAR measurements to predict drug susceptibility in an established cell line, we used BaF3 cells that were engineered to express either wild-type BCR-ABL or the BCR-ABL T315I mutant, which is resistant to the tyrosine kinase inhibitor imatinib 19, 20 .
Treatment of BaF3-BCR-ABL cells with imatinib at the therapeutically achievable concentration of 1 µM for only 2-4 h significantly decreased MAR without altering the distribution of mass (Fig. 2) . With longer durations of exposure to imatinib, the reduction in MAR became more pronounced (Fig. 2b) and cell mass was reduced (Fig. 2c) . When we applied the same conditions to BaF3-BCR-ABL T315I cells, we observed no significant change in MAR or mass distributions (Fig. 2) . However, exposure of these cells to the third-generation tyrosine kinase inhibitor ponatinib, which retains activity against BCR-ABL T315I, recapitulated the same reduction in MAR that we observed following imatinib treatment of BaF3-BCR-ABL cells (Fig. 2b) 20 . Thus, MAR can distinguish therapeutic susceptibility from resistance in single BaF3 cells after only a few hours of drug exposure.
Next, we tested the ability of MAR measurements to predict therapeutic susceptibility when applied to GBM-PDCLs that had heterogeneous and complex MAR profiles, including cycling (non-G0) as well as non-cycling cells (G0) (Fig. 1 and Supplementary Fig. 2 ) 16, 17 . 
A r t i c l e s
GBM is highly resistant to most therapeutics, but we previously reported that some GBM-PDCLs are sensitive to targeted MDM2 inhibition 21 . In bulk tumors and cultures, MDM2 inhibitors are known to induce responses in cells in which wild-type TP53 is expressed and MDM2 expression is amplified, whereas cells with mutant or deleted TP53 are completely resistant to MDM2 inhibitors. However, cells that express wild-type MDM2 and wild-type TP53 have unpredictable sensitivity to MDM2 inhibitors in GBM and other tumor cell types 22 . We used the MDM2 inhibitor RG7112, a compound that is being evaluated in clinical trials, to determine how single-cell MAR responses of four GBM-PDCLs across this spectrum of MDM2 and TP53 mutant backgrounds might empirically correspond with genetics and CellTiter-Glo bulk sensitivity measures 23 . BT484 and 3731 cells, in which wild-type TP53 is expressed and MDM2 expression is amplified, had primarily negative MARs after incubation with 1 µM RG7112 for 13-24 h (Fig. 3 and Supplementary Fig. 4 ). With increasing time, the number of cells with negative MAR further increased for 25-36 h, at which point >80% of cells were losing mass in both PDCLs ( Fig. 3 and Supplementary Fig. 4 ). In comparison, BT333 cells, which express wild-type MDM2 and mutant TP53, showed no significant change in MAR compared with a DMSO-treated control over 36 h of RG7112 exposure ( Fig. 3 and Supplementary Fig. 4 ).
Contrasting the predictable sensitivity and resistance of the aforementioned lines, the responses of cells expressing wild-type MDM2 and TP53, was not clearly correlated with the MDM2 and TP53 genotype. For example, targeted and whole-exome sequencing of BT159 cells, which express wild-type MDM2 and TP53, revealed no mutations or copy number alterations in TP53, TP63, TP73, CDKN2A, MDM4, mitochondrial apoptosis mediators or other p53-related genes that could mediate MDM2 inhibitor resistance. However, BT159 exhibited no evidence of single-cell response by 36 h using MAR measurements, similar to the complete resistance exhibited by TP53-mutant BT333 cells (Fig. 3 and Supplementary Fig. 4) . MAR measurements for all lines were consistent with the response in viability as measured by CellTiter-Glo after 72 h of RG7112 exposure (Supplementary Fig. 5 ). 
MAR predicts primary cell sensitivity to targeted therapy Next, we asked whether MAR measurements could effectively predict therapeutic response in primary tumor cells that were measured immediately after isolation from the in vivo setting. We harvested transgenic murine ALLs that expressed BCR-ABL or BCR-ABL T315I from the spleen of mice and used flow sorting to purify the leukemia cells (Supplementary Fig. 6 ) 24 . Single-cell MAR data was collected after 10-20 h of treatment with 1 µM imatinib or 100 nM ponatinib. Across three independent biological replicates, we observed a significant reduction in average MAR for leukemias expressing BCR-ABL following treatment with imatinib or ponatinib, as well as for leukemias expressing BCR-ABL T315I following treatment with ponatinib (Fig. 4a) . By contrast, imatinib had no effect on leukemias expressing BCR-ABL T315I (Fig. 4a) . We confirmed that BCR-ABL T315I leukemias were truly resistant to the imatinib analog nilotinib in situ by treating mice engrafted with these leukemias (Supplementary Fig. 7 ). In contrast with the marked effect of imatinib on MARs of wild-type BCR-ABL leukemia cells, exposure to imatinib in vitro for 24 h had no effect on the viability of leukemias expressing wild-type BCR-ABL in bulk culture, as determined by flow cytometry for annexin V and DAPI (Supplementary Fig. 6) . Thus, the effect on MAR precedes these more standard metrics of drug response.
To gauge how robustly MAR measurements can predict primary ALL single-cell drug sensitivity, we generated a receiver-operating characteristic (ROC) after performing linear discriminate analysis (LDA) on each replicate's data set. Thus far, we had used the single metric of MAR per mass; however, we also considered MAR and mass as independently variable biomarkers. LDA projected the populations of the two-dimensional MAR versus mass data onto a single axis that provided the best ability to distinguish two populations, and then defined the ideal threshold for this classification (Fig. 4b) . Subsequent ROC curve analysis was performed, and its area under the curve (AUC) was used as a metric of the ability to properly identify a single cell's classification as sensitive or resistant to therapy 25 . A random classifier has an AUC equal to 0.5, and a perfect classifier has an AUC of 1. The average AUC of non-selective conditions (DMSO-treated compared with imatinib-treated T315I leukemia) was 0.57, consistent with the expectation that resistant cells are indistinguishable from untreated cells (Fig. 4a,c) . Under selective conditions, the ROC curves for MAR versus mass showed excellent resolution of sensitive and resistant populations, with an average AUC of 0.85 (Fig. 4a,c) . ROC curves using mass or MAR as single parameters had significant power to classify single cells, but the single parameters were less consistent between replicates and were, on average, less accurate than using both parameters for classification ( Fig. 4c and Supplementary Fig. 8 ).
MAR predicts sensitivity of circulating leukemia cells
Although GBM PDCLs and murine spleens essentially provided us with an unlimited number of tumor cells, we wanted to measure MARs from small samples, simulating the limited tissue available with patient biopsies. To this end, we isolated tumor cells from the peripheral blood of mice by cheek bleeding, which resulted in only 25 µl of total volume and did not compromise mouse survival. We performed these bleeds when circulating disease was as low as 4% of circulating mononuclear cells. This approach typically provided on the order of 10 3 total tumor cells for measurement following purification by flow sorting. To measure samples of low cell count and volume, we implemented a next-generation SMR array device that greatly simplified fluidic handling, increasing throughput by 20-fold and enabled the use of low-volume samples 26 .
Single-cell MAR data was then collected on both cheek bleed (~25 µl) and cardiac bleed (~500 µl) samples that were exposed to either DMSO or 100 nM ponatinib for 14-20 h in vitro. Classification of single-cell drug response from cheek bleed samples (AUC = 0.85) were similar to those from splenocytes (AUC = 0.85) and cardiac bleed samples (AUC = 0.80) (Fig. 4d and Supplementary Fig. 9 ). The ability of MAR measurements to assay drug sensitivity of single cells isolated from very small amounts of blood makes it feasible to longitudinally screen for phenotypic resistance in individual patients through iterative sampling. or cheek bleed and treated with 100 nM ponatinib or DMSO for the specified interval. P values were calculated using the Mann-Whitney U test, comparing treated cells to the DMSO control. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ns, not significant, P > 0.05.
A r t i c l e s
Patient cells reduce MAR when treated ex vivo or in vivo
To define MAR assay compatibility with clinical samples, we ran two separate experiments using primary patient samples. First, we assayed ficolled peripheral blood samples from a patient with relapsed acute myeloid leukemia (AML). A sample obtained from the patient when they were not receiving treatment consisted largely of slightly positive MARs (Fig. 5a and Supplementary Fig. 10 ). After the patient had received 48 h of treatment with an experimental MDM2 inhibitor, a second peripheral blood sample was taken. This revealed a broader distribution of MARs compared with the pretreatment sample. Furthermore, a large population of cells with negative MARs of less than −1 pg/h appeared, indicating a shift in population MAR dynamics in vivo among the leukemia present in the peripheral blood ( Fig. 5a and Supplementary Fig. 10 ). This shift toward negative MARs following treatment is consistent with our observations from ex vivo treatment of susceptible GBM-patient-derived cell lines (Fig. 3) and murine primary cells (Fig. 4) . Finally, we performed ex vivo treatment of a patient sample analogous to the approach applied to primary murine samples. Bone marrow leukemia cells from a patient presenting with newly diagnosed mutated-FLT3-positive AML with myelodysplasticsyndrome-related changes was treated in media with a range of therapeutics, including DMSO, 1 µM cytarabine (cytotoxic chemotherapy), 100 nM midostaurin (FLT3 and multikinase inhibitor) and an experimental MDM2 inhibitor (Fig. 5b) . These cultures were incubated, and we measured MARs on three next-generation SMR array devices in parallel during 10-h windows that centered on 20 and 44 h. Cells in midostaurin showed no significant change in their distribution of MAR as compared to a DMSO control, consistent with the limited activity of single-agent midostaurin in FLT3-mutated AML 27 . In comparison, cytarabine did result in a reduction in MAR that was highly significant (P = 0.00015) at 48 h as compared with the control. Finally, cells treated with the experimental MDM2 inhibitor showed reduced MAR at 24 h, which rebounded by 48 h, potentially indicating a brief period of p53 target induction that is followed by the rapid induction of adaptive resistance.
DISCUSSION
We developed a functional assay for assessing single cancer cell therapeutic sensitivity based on measurements of MAR and the mass of individual cells. We validated the predictive power of combining MAR and mass measurements by confirming susceptibility or resistance of genetically defined cell lines, human GBM-PDCLs and primary murine ALLs in response to targeted therapeutics. In addition, by measuring mass accumulation rates of single cells across a population and establishing a growth profile for different GBM-PDCLs and cell lines, we have shown the heterogeneity of single-cell growth both in and across these populations. Additional experiments will be needed to prove the utility of MAR measurements for clinical decision-making. However, our initial data with primary patient leukemia samples, treated either ex vivo or in vivo, revealed responses that were consistent with our previously assayed in vivo models.
MAR measurement in the SMR is not a terminal assay, as cells are kept viable throughout the measurement and thereby remain compatible with downstream analyses. Thus, a key advantage of MAR measurements is that cells can be studied downstream of the SMR using other single-cell assays, as we demonstrated by quantifying the tumorsphere-forming potential of GBM-PDCL cells after passage through the device (Supplementary Fig. 1 ). This ability will ultimately allow for correlations between single-cell changes in MAR, other functional outcomes and non-functional biomarkers (e.g., genetics, gene expression and chromatin modifications). Further studies are needed to assess the effects of passage through the SMR on aspects of tumor cell biology, including changes in the transcriptome, genome and proteome. Previous studies have found that cellular and genomic properties of single cells can be measured using techniques such as RNA sequencing and are well-preserved following exposure to microfluidic environments 28 .
Recent studies have used other functional approaches to predict therapeutic sensitivity of individual cancers. For example, one group used standard proliferation-based assays to quantify therapeutic susceptibilities of bulk cultures of PDCLs 10 . The results from this ex vivo screening predicted the response of in vivo xenografts to combination therapies. However, cell-to-cell heterogeneity is not captured by population approaches, and the utility of this strategy for clinical decision-making is limited by the months of prolonged culture required for PDCL creation.
Another recent study presented a functional approach called 'dynamic BH3 profiling' , in which therapeutics are applied to cell lines or clinical tumor isolates, and then the percentage of cells that undergo mitochondrial outer membrane permeabilization (MOMP) is measured after introduction of a pro-apoptotic BH3 peptide 29 . Dynamic BH3 profiling robustly predicted which patients would respond to a given therapy across multiple cancer types. However, this approach requires cell permeabilization, which complicates the application of both downstream assays and phenotype validation, and does not clearly distinguish between subsets of cells with phenotypic heterogeneity.
MAR measurement addresses many of these limitations by assessing therapeutic susceptibility in single, live cells without the need for PDCL generation, but is subject to its own set of constraints. Most notably, in vitro culture is still necessary for a length of time adequate to elicit a growth response to applied therapeutics. In BaF3 cells, this occurred within 2-4 h, but GBM cells required longer culture to appreciably change MAR in the presence of MDM2 inhibition. Thus, the MAR measurement can reduce, but does not completely eliminate, the time in in vitro culture. In addition, the SMR currently requires cells to be in a single-cell suspension or small clumps for mass A r t i c l e s and MAR measurement. Future studies will need to explore the utility in solid tumor systems, where the extent of dissociation required may perturb cellular viability and/or response. MAR measurements also initially suffered from low throughput. However, single-cell mass and MAR can now be obtained with a throughput exceeding 60 cells per h per device without sacrificing precision 26 .
Perhaps the most important shortcoming of our approach, and the vast majority of functional assays, is a potential bias toward assessing only cell-intrinsic drug susceptibility. Microenvironmental interactions are known to influence in vivo drug response, but cellular 'memory' of these interactions may degrade during the course of ex vivo treatment 9 . There have been recent advancements in this arena involving implantable devices, but these approaches are currently only compatible with solid tumors and require tumors of a minimum size that are easily accessible 30 . To address the role of microenvironmental interactions, future studies using MAR measurements should explore whether alternative culture conditions can help to address the contribution of cell-extrinsic factors under controlled conditions; for example, tumor cells could be maintained in vitro in the presence of both drug and co-culture with stromal and/or immune cells before measurement. Alternatively, patient drug response in situ could be monitored. For example, patient tumor cells could be analyzed with MAR measurements immediately before and hours to days after treatment to help inform pharmacokinetics and pharmacodynamics. In fact, we applied this approach to a patient with AML (Fig. 5) to assess overall feasibility for clinical scenarios that could be explored in the future.
A substantial amount of work needs to be performed in the future to define the utility of mass and MAR as biomarkers for treatment response across disease types, in comparison with alternative functional assays, for drugs in combination, and across a wider range of drug mechanisms, where response may differ on the basis of the mechanism of cell death. However, given the scarcity of functional assays with the necessary characteristics to merit widespread application, MAR measurements in the SMR could be potentially useful as both a biological tool and a clinical platform.
METHODS
Methods and any associated references are available in the online version of the paper.
